To evaluate the effect of this novel PMS2 gene variant (c.184G>A; p.Gly62Arg), we used an integrated approach combining genetic and clinical findings of the affected families, the evaluation of the tumor phenotype, and bioinformatics analyses to predict its effect on protein structure and stability and assess its molecular impact on the clinical phenotype associated with LS. The gene discussed is PMS2; the disease is neoplasm.